This article is more than 5 years old. Information may no longer be current.

Antiviral compound shows promise against herpes in vitro

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DOYLESTOWN, Pa. — In vitro studies of an antiviral drug show it may have efficacy against ocular herpes, according to the company developing the compound.

In a press release, Quigley Corp. announced that the antiviral QR-435 "demonstrated reproducible potent direct antiviral activity against an ocular isolate of HSV-1. It also demonstrated similar potent direct antiviral activity against a second similar ocular isolate of HSV-1 and multiple clinical genital isolates of HSV-2."